Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
PCTL is all about the ANNIHILYZER!!!
PCTL"s SNOWBALL EFFECT has been activated!!!
The snowball effect describes when somethings grows in significance or size in an increasingly faster rate. The name comes from imagining a snowball rolling down a hill - it gets larger and larger with more snow and becomes faster and more powerful as it moves onward. ...
I know they don't and that is why ENZC is needed and it puts them in a good place to be a game changer for not only for an alternate but a better solution.
What is the good of drawing conclusions from experience? I don't deny we sometimes draw the right conclusions, but don't we just as often draw the wrong ones?
Conservatives confront moral dilemma of vaccines, treatments from fetal tissue cells
The race to develop vaccines and treatments for COVID-19 has newly highlighted a longstanding dilemma for religious conservatives: much of the cutting-edge research relies on the use of material derived from human fetal tissue -- something they have spent years fighting against.
In interviews with ABC News this week, leaders in the Catholic Church and other anti-abortion advocates say they aren't ready to dismiss the latest scientific discoveries that could save countless lives. But they also are quick to note that much of the new findings could be what they consider ethically "tainted."
"There's a lot of concern and interest in this issue -- what's the vaccine going to look like? What kind of moral choices are we going to have before us?" said Greg Schleppenbach, the associate director of Secretariat of Pro-Life Activities with the U.S. Conference of Catholic Bishops.
Recent polling reveals a split amongst Americans: roughly 6 in 10 adults say abortion should be legal in all or most cases, while 38% say it should be illegal in all or most cases.
At issue is the use of cells derived from human fetal tissue to discover, develop and test medical innovation -- something scientists agree is often necessary in the most groundbreaking medical advances.
During his political career, President Donald Trump has assumed a staunchly anti-abortion stance. In 2019, his administration suspended federal funding for research reliant on new fetal tissue cells derived from an elective abortion, while allowing for previously established cell lines. Fetal tissue from miscarriages are permitted under this statute, although many scientists say it's difficult to use because there are often abnormalities and other issues.
In early 2020, The Trump administration created a new federal ethics board to review proposed fetal tissue research grants. Of the 15-person board, 10 have records of opposition to abortion, fetal tissue research or both.
Conservative groups long-opposed to abortion have advocated against what they call "ethically problematic" fetal material -- tissue obtained via elected termination of pregnancy, and cell lines descendent from them.
It's not a simple ask: some of the most commonly used cell lines in medical research originated that way. The experimental antibody treatment from Regeneron that was taken by Trump to treat COVID-19 was developed using cells derived originally from human kidney tissue taken from an aborted fetus in the 1970s. Several of the vaccine candidates for the virus also use that line.
The cells from that tissue, the HEK293T cell line, have continued to divide and grow in a culture, and have been used in scientific discovery, for decades.
Regeneron says it does not consider the treatment to have relied on fetal tissue, since the cells were acquired so long ago.
They "are considered 'immortalized' cells (not stem cells) and are a common and widespread tool in research labs," a Regeneron spokesperson told ABC in a statement. The cell line "wasn't used in any other way, and fetal tissue was not used in this research."
Social conservatives view research with fetal tissue as unethical and have long disputed taxpayer money's use to support it. Scientists counter, controversy aside, that countless important medical discoveries have relied on fetal tissue, leading to significant work in research and treatment of diseases like AIDS and Zika, and further, could be instrumental in combating coronavirus. Fetal tissue cells are more flexible and less specific than adult cells, and can offer a unique "blank slate" for further study and testing of new therapeutics.
"Fetal tissue has unique and valuable properties that often cannot be replaced by other cell types," the International Society for Stem Cell Research urged the new Trump ethics board in July, adding, it "remains the gold standard for evaluating the accuracy of models of human fetal development."
Lying at the crux of the contention -- how that material is obtained. Under current statute, tissue from "spontaneous" abortions, or miscarriages, are permitted. But those moments often occur not in hospital -- rather, at home -- making proper sample collection difficult, experts say, in what poses an already brief window of time before the cells are degraded. And, miscarriage often occurs because of complications during fetal development which prevented it from surviving to full term. Thus that tissue would offer limited use, unless it was that specific abnormality a scientist had hoped to study.
The U.S. Conference of Catholic Bishops has advocated for at least one COVID-19 vaccine to be developed completely free from connection to aborted fetal cells. In April, the USCCB sent a letter to FDA commissioner Stephen Hahn, urging, "no American should be forced to choose between being vaccinated against this potentially deadly virus and violating his or her conscience."
Rev. Dr. Tadeusz Pacholczyk, director of education at the National Catholic Bioethics Center and member of a federal ethics advisory board on the matter, told ABC: "The decision by companies to intentionally utilize these problematic cell lines results, if there are no alternatives, in a kind of moral coercion."
Still, other anti-abortion conservatives say that the cell line used to develop the vaccines or treatments for COVID poses less of a moral dilemma than if it had come directly from an aborted fetus.
Dr. G. Kevin Donovan, director of the Pellegrino Center for Clinical Bioethics, professor of pediatrics at Georgetown University, said it's not a clear-cut issue.
"There are gradations of cooperation," said Donovan, also a member of the Trump administration's fetal tissue ethics advisory board.
"Some of them are so remote to what you see is the original evil act, that you can be morally justified in accepting some necessary, lifesaving good that comes from it," he added. "Not just for you, but by being immunized, you're also not going to spread the virus to other people."
Several scientific experts have criticized Trump for taking a treatment drawn from the research his administration has worked to curtail.
"President Trump has been an outspoken opponent of fetal tissue research -- and he used it. I just think it's incredibly hypocritical across the board," Dr. Lawrence Goldstein, fetal tissue ethics board member and senior faculty member at the University of California at San Diego. He told ABC, the board was "stacked with anti-fetal tissue research members," who "rejected virtually every proposal it saw."
"The most outspoken opponents [of fetal tissue research] are now just averting their eyes, pretending it doesn't exist, and saying, well, it happened a long time ago, and we have no choice, we've just got to deal with it," Goldstein said. "There's a bit of a bind here."
Deepak Srivastava, president of the Gladstone Institutes and immediate past president of the International Society for Stem Cell Research, noted that if the Trump administration's ban was in place when the cell line Regeneron used was made -- the innovations that have come from it would not have been possible -- including testing the treatment Trump received.
"It's just tremendous hypocrisy," Srivastava said. "It would not be available to make the drugs that we've had -- and Trump would not have received those antibodies."
Those who support banning abortion argue if there is an inconsistency with COVID-19 research, it rests with the federal funding fueling vaccine development that utilizes abortion-derived cells.
"You're funding that which you say should not be funded," Pacholczyk said. "And that's a concern."
In August, the ethics board rejected funding for nearly every proposal involving fetal tissue: 13 out of 14. No COVID-19-related proposal was reviewed, several of the board members confirm to ABC, though they were unsure why that was. The NIH told ABC none of the projects recommended for funding that proposed to use human fetal tissue were COVID-19 related, adding, "There is no special review process" for COVID-19 projects involving human fetal tissue.
Medical experts on both sides of the issue affirm the importance of fetal tissue in scientific research, entrenching the ethical tug-o-war.
"It's an ethical dilemma of competing goods, how tainted they are," said Dr. Greg Burke, co-chair of the Catholic Medical Association Ethics Committee. "In medicine, that sanctity of life argument is a powerful one. Not everybody agrees, obviously. So then how do we balance where we can't go out and live without somehow interacting, being tainted by things we would consider immoral or unethical?"
Those ethical concerns raised by the use of human fetal cell lines are "fairly nuanced," said Dr. Maureen Condic, NIH ethics board member and associate professor of Neurobiology and Anatomy at the University of Utah School of Medicine.
Condic noted that the HEK293T cell line is so widely in use for decades that she said it's essentially a "component of every single type of basic biological research and all types of medical research."
"They create a lot of concern for people," she acknowledged. "But then, if that's the ethical question, then do you disavow any interaction with the medical profession, period, where you might be complicit in the utilization of a cell line that is so widely in use? It's essentially impossible to avoid it."
https://www.msn.com/en-us/health/medical/conservatives-confront-moral-dilemma-of-vaccines-treatments-from-fetal-tissue-cells/ar-BB1a9gkR?li=BBnb7Kz&ocid=DELLDHP
When will PCTL’s potential be unleashed?
PCTL has a lot of potential and a lot of irons in the fire waiting to be unleashed.
Fluid Sales from distributors contributed to 2nd quarter results and with the additional ones coming onboard should help to unleash the unseen potential.
PCTL has 3 hospital networks in the quoting phase awaiting final approval.
“The quoting phase can be a necessarily lengthy process at times,” explains Darryl Patterson, PCTL’s Director of Healthcare. “At this stage, multiple parties within a hospital organization need to give their final approval before we can move forward. Once approved, we can schedule installations. “
No funds would not be available from Werks.
If they were we would have already gone that route.
In order for Werks to produce a large order of machines PCTL need a large infusion of cash. PCTL has to move nimbly and with balance.
We are still in a dreadful financial state that must be properly monitored and dealt with while we grow the company as we are able with the funds from our growing revenues.
Slow and steady
People want facts however at the present time with PCTL financial conditions, some facts are best kept internal until they are releases in the financials. Hopefully after PCTL have fulfilled enough POs from the UK and have at least 30-50 systems in the pipeline then we may start to see hard numbers.
Why?
How does anyone think the market would react if Gary G had put out hard numbers in the PR such as a PO for 5 systems and $100,000 (based on actual purchase of system selling at $40,000 a piece)?
or
PO for 10 systems and $240,000 (based on leasing systems with the $240,000 representing 50% of first year's leasing costs)?
We don't now if the systems are being leased or bought.
We don't know what that 50% represent.
It will be a little clearer when the financials are released.
Right now we can be thankful that the POs has started and suppose to continue.
crawl
Walk
RUN
Once the HUGE US market start to get penetrated outside of NYC PCTL is going to rock even more:
Health systems, also referred to as integrated delivery networks (IDNs), are networks of providers and care facilities that are formed with the goal of improving clinical and quality performance. IDNs help to ensure that patients receive the best care outcomes for the lowest costs, and usually offer a full range of healthcare services from preventative to post-acute care.
Each health system is different in terms of size, specialty, and membership makeup. According to Definitive Healthcare data, approximately 78 percent of hospitals belong to an IDN—up from 75 percent in 2018.
Top 10 health systems by net patient revenue
HCA Healthcare: $42,673,974,296
Kaiser Permanente: $29,176,611,660
CommonSpirit Health: $28,358,722,418
Ascension Health: $18,788,901,219
Providence St. Joseph Health: $16,286,062,476
Kaiser Permanente Northern California: $14,359,957,345
Tenet Healthcare: $14,140,396,155
Kaiser Permanente Southern California: $14,011,636,037
Trinity Health: $13,737,577,562
University of California Health: $13,032,563,332
The top health systems listed here reported a combined net patient revenue of over $204 billion as of July 2020—making these networks a lucrative sales and marketing opportunity for organizations selling into the healthcare market.
https://blog.definitivehc.com/top-10-largest-health-systems
PCTL has not penetrated the potential US market for its Annihilyzer System however when they do the results could be HUGE!
PCT LTD Announces Successful Presentation of Annihilyzer(R) Hospital Infection Control Systems at APIC Event in South Carolina
LITTLE RIVER, SC / ACCESSWIRE / November 29, 2018 / PCT LTD (OTC Pink: PCTL), a leader in environmentally safe, non-toxic, antimicrobial solutions for infection control, recently attended the South Carolina Association for Professionals in Infection Control and Epidemiology (APIC) event in Columbia, SC. PCT introduced attendees to the new Annihilyzer® Infection Control System during the event. The response from the attendees was positive and enthusiastic. Several of them requested meetings at their facilities to present the system to their management and colleagues and site visits to PCT client hospitals to observe Annihilyzer® Systems operations in the hospital setting.
The market potential of PCT's system in hospitals is approximately 7,000 systems across the US and for Nursing Homes and Assisted Living facilities is approximately 13,600 systems. PCT has a current sales funnel of over 30 hospitals in the Carolinas and the Northeast that are in active discussions with PCT about acquiring the Annihilyzer® System and Services. This System can significantly address and reduce the problem of Hospital Acquired Infections (HAI's) that currently costs U.S. hospitals over $35 Billion in infection prevention and control programs, HAI patient treatment and other significant HAI-associated costs.
PCT also introduced its Annihilyzer® Infection Control System to a national standards group for guidance in introducing into the healthcare market a system capable of onsite production of a non-harmful, Green Seal Certified tuberculocidal disinfectant that kills 99.9999% of organisms such as Clostridium difficile (C. diff.), MRSA, VRE, CRE, Klebsiella pneumoniae, and Pseudomonas. The Company's primary fluid solution is effective against common healthcare pathogens such as Tuberculosis (TB), HIV-1, Hepatitis C, Norovirus, Rhinovirus, Influenza A, Candida albicans, and more; food processing bacteria including E. coli, Listeria, and Salmonella; and organisms of veterinarian concern such as parvovirus, distemper and Bordetella. This group was very excited about the ability to reduce Hospital Associated Infections (HAI) using a non-synthetic solution which is not harmful to patients, staff, equipment, or furniture. The ability to track the fluid's efficacy and provide cleaning and disinfecting protocols will reduce human error and increase the effectiveness of infection prevention and disinfection programs.
PCT LTD ("PCTL") focuses its business on acquiring, developing and providing sustainable, environmentally safe disinfecting and tracking technologies products. The company acquires and holds rights to innovative products and technologies, which are commercialized through its wholly-owned operating subsidiary, Paradigm Convergence Technologies Corporation (PCT Corp).? Currently trading on OTC, "PCTL" aspires to and is actively engaged in preparations for up-listing its common stock to a national securities exchange. The Company established entry into its target markets with commercially-viable products and now prepares to gain market share.
PCT Corp's business mission is to profitably provide state-of-the-art Electro-Chemical Activation equipment, disinfecting fluid solutions and PCT Corp's patented tracking system to hospitals and other facilities for the documentable remediation of Hospital Acquired Infections (HAI's) from organisms such as Clostridium difficile (C. diff.), MRSA, VRE, CRE, Klebsiella pneumoniae, and Pseudomonas, as well as to sell ECA fluid solutions to agricultural markets for the remediation, control and suppression of microbial contamination and disease of certain commercial crops. The Company's primary fluid solution, branded Hydrolyte®, is an EPA registered "hospital-level" disinfectant effective against common healthcare pathogens such as Tuberculosis (TB), HIV-1, Hepatitis C, Norovirus, Rhinovirus, Influenza A, Candida albicans, and more; food processing bacteria including E. coli, Listeria, and Salmonella; and organisms of veterinarian concern such as parvovirus, distemper and Bordetella. PCT Corp.'s proprietary equipment product line includes: 1) PCT Hydrolyte® Generators, 2) PCT Annihilyzer® Infection Control Systems, and 3) SurvivaLyte® equipment. The Hydrolyte® Generators produce large volumes of electrolyzed water for the agriculture, oil and gas, and fluid distribution markets. The Annihilyzer® Infection Control Systems, which boast patented RFID material tracking technology, Electrostatic Smart Applicators, on-site automated ECA generators, and Green Seal standards containing stringent performance, health, and sustainability criteria, are ideal for hospitals and healthcare facilities. The SurvivaLyte® unit is a portable, small volume generator with applications such as disaster recovery, emergency preparedness, remote on-site needs, farm and ranch, and personal use. PCT Corp's unique patented systems and human-safe products provide next-generation cleaning, sanitizing, disinfecting and decontaminating fluid solutions to the ever-present problems of microbial infection and infestation.
Forward-Looking Statements
This press release contains "forward-looking statements" as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21B of the Securities Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be "forward-looking statements."
Such statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Such statements involve risks and uncertainties, including but not limited to: any implied or perceived benefits resulting from the presentation at APIC; continued positive results relating to the installation of PCT's Annihilyzer® systems in hospitals; the results of any manufacturers' representative and/or license agreements, actual sales revenue to be derived from agreements; PCT LTD's and its subsidiary's business prospects; PCT LTD's ability to raise sufficient funds to satisfy its working capital requirements; the ability of PCT LTD to execute its business plan or list its common stock on a national stock exchange; benefits of the Annihilyzer® Infection Control Systems, Hydrolyte® generators and fluids; any other effects resulting from the information disclosed above; risks and effects of legal and administrative proceedings and government regulation; future financial and operational results; competition; general economic conditions; and the ability to manage and continue growth. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual outcomes may vary materially from those indicated.
Important factors that could cause actual results to differ materially from the forward-looking statements PCT LTD makes in this press release include market conditions and those set forth in reports or documents it files from time to time with the United States Securities Exchange Commission. PCT LTD undertakes no obligation to revise or update such statements to reflect current events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
Numbers matters and sometime can be perceived positive or negative whether it is really positive or negative. As we must account for every idle word, so must we account for every idle silence.
In the case with PCTL it is a matter of balance.
A lot of people wants numbers on the recent PO and if a large number as compare to previous known numbers (600 hospitals 14000 care homes) on the UK NHS deal it can be perceived positive.
If it is a small number as compared to previous known numbers than it could be perceived negative.
The most important thing to grasp is the UK deal is moving regardless of the number and with more POs coming the number is to grow.
Sometimes numbers mean nothing.
Huh!
What if, hypothetically of course, PCTL released a PR that said they had a contract with the US Government and no numbers mention. The perception would be through the roof even with no numbers.
We have the potential maximum numbers for the UK deal although we don't have the actual number for the POs we do know whatever number is, it will continue to grow.
Congrats DE.
You have shown and shared what is possible through hard work.
It is a beautiful story that just keep getting better and better with each chapter.
Looking forward to future chapters.
moxa1,
Agreed,
We can ramp up as our sales and revenues increase. PCTL has to balance funds to keep us afloat and keep the business growing.
Slow and steady
Evaluate,
It is speculation.
1. If one was to look at PCTL from a financial standpoint, they don't have the funds to do a massive build out.
2. They said 14 systems by the end of the year which some will probably be installed stateside as we have 3 hospital networks in the quoting phase, barring any unforeseen restrictions or difficulties, should receive final approval and be installed within 30-60 days (from August 5, 2020 PR).
3. The most systems we ever delivered was 5.
4. If it was a large order Gary G. would be shouting in the streets.
5. I don't think PCTL could handle a large order due to finances so it is probably best to start small and pick up the pace as financing allows.
6. Even with PCT LTD Europe providing 50% cash deposit, PCTL has to pony up some dough to get the systems built and shipped.
Again it is just speculation on my behalf.
Snow,
I don't believe it was very large. The most it could have been was 14 and the least 2. It probably will start low and slow and ramp up moving forward especially in the midst of Covid.
One of my Military Commanders taught me a very valuable lesson years ago: if it isn't written down it didn't happen.
Now in this age of technology we also have video and audio all over the place.
If you could kindly provide some proof, written, video or audio of the CEO stating that we would be on either the NASDAQ/NYSE/AMERICAN this year.
The tanking of the stock has nothing to do with the Conference Call. When the stock reverses and there is no pr, no financials and no nothing what reason will people give. And it is going to reverse.
Stock prices tick up and down constantly due to fluctuations in supply and demand. If more people want to buy a stock, its market price will increase. If more people are trying to sell a stock, its price will fall.
I guess more people are selling.
PCTL is not an instant gratification stock.
People want specifics of the PO.
If they had released specifics the number would not have been no larger than 14 and could have been as low as 2.
Sometimes is best to keep things under wraps.
The fact is PCTL has a PO with more to come.
So whatever the initial PO number was if will grow over time.
Here is what is going to happen to the stock price it will go up and down, drift in a range and then start an uptrend.
PCTL hired a professional Marketing firm to establish PCTL identity and expand markets.
I believe a major problem with PCTL is little or limited marketing.
Why was the Annihilyzer such a big hit in NYC?
Ace Janitorial.
PCTL wants distributors to go market PCTL products in their area. However I believe for the Annihilyzer they also need a different approach such as the marketing firm they hired.
The Annihilyzer is a special piece of equipment and I don't say that as an investor only. If anyone thinks there is a better product out there I would like to know.
The marketing firm is going to redo our website and beyond that I don't know.
What the company do need and I asked the question and they were just getting to it when the CC was ending.
Does PCT LTD plan on doing a marketing campaign for the Annihilyzer to hospitals via internet, TV, radio, phone or direct mailings? They are on the right track with the business consultant as far as getting the word out. He/she has a great incentive to drum up business.
Once hospitals find out about the Annihilyzer I believe more will want one.
The amount of POs to the UK is not a lot yet.
If PCTL put out the number it may have had a worse effect on the stock price.
What is important is that the process has started and more to come down the road.
The stock price will reflect what is going on with the company at some point and certainly if the financials shows increase sales and revenues.
They owned up to the late financials and provided a solution to prevent from happening in the future.
Enough said
PCTL is small company with potential.
Yes it would be nice to know how many systems and how much money however it is OK to keep a veil up at the present time. We know the UK systems POs are moving and more will be in the pipeline.
Maybe it was just 2 or 3 systems. How do you think the market would react to that?
How would you react to that?
Less is best sometimes.
As more and more POs come in and when we have a good number of systems installed maybe they might provide more info.
PCTL is growing and revenues are increasing. We may get more details on the number of systems once they are installed. We won't see the money figures until the financials are released and even then it will be combined with U.S. figures.
POs not substance
50% cash deposit not substance
Oil and gas test not substance
What substance would you have like to have seen?
PR out
To Investor Relations:
Do you have a link to the recorded CC?
From Investor Relations:
Good Morning,
There will be. They are going to put a link up on our website this morning.. Once it's up I will send it out the shareholders.
PCTL has always released a PR after every CC or Podcast.
Soon come
To Investor Relations:
Do you have a link to the recorded CC?
From Investor Relations:
Good Morning,
There will be. They are going to put a link up on our website this morning.. Once it's up I will send it out the shareholders.
PCTL has always released a PR after every CC or Podcast.
Soon come
Covid 19
Too many unpredictables
Many distributors added however Covid has slowed the process down to get them up and running.
Even with the UK coming onboard PCTL still have to get the equipment to the UK and the equipment has to get installed remotely. Hopefully there isn't a lock down here or there to slow the process.
If all goes well then it will all show up in the financials.
No harm no foul.
Continued growth with increased revenues timely reported in financials will take care of the stock price moving forward.
Why?
Distributors growing
Annihilyzer sales increasing
UK coming onboard
PCTL had just installed their first Annihilyzer system o May 18, 2018.
Yes they did over anticipated an expectation of systems sales.
Why?
Who knows what it was based on.
They got a rude awakening when they started marketing the Annihilyzer and how difficult it was to get it into hospitals.
After struggling and with the assistance of Ace Janitorial they were able to break into the NY market and know have a systems in at least 14 of the 62 acute care hospitals in NYC.
As far as shares being dump back then is a falsehood.
According to the 2018 2nd 10Q:
The number of shares outstanding of the registrant’s common stock as of August 20, 2018 was 43,459,238.
PCTL is a struggling but growing company. The have challenges to deal with however as long as revenues increase and debt is kept in check they should be OK.
Should be a PR this morning.
They have always released one after a Conference Call or Podcast.
Agreed,
The only possibility is number of systems and that may not happen.
PCTL usually announce the number of systems after the installs are complete.
They have issue some PRs saying there is going to be an install here and there however if they give a specific number in this case it would be welcomed.
I don't see them giving any dollar figures though.
We do know based on guidance given of how many systems installs are expected by years end of a rough estimate however how many are going to the UK and how many are going to US based hospitals is unknown.
HOCI the gift that keeps giving.
Hypochlorous Acid was the catalyst that gave PCTL a financial boost that relieved the company of the burden of a continuous debt load. It also enabled them to prepare for a build out of their flagship product, the Annihilyzer/Large Volume Hydrolyte System for orders they received due to Covid-19 and eventually the UK and beyond.
So just what are the installation numbers of PCTL’s Annihilyzer/Large Hydrolyte Systems?
I really don’t know however below is what I do know:
FACTS not fiction
At least 36 Hospitals/Distributors using The PCTL Annihilyzer/Large Volume Hydrolyte Systems!
Hospitals (25)
Johnston UNC Health Care Hospital
Carson Tahoe Regional Medical Center
New York-Presbyterian?
NewYork-Presbyterian Morgan Stanley Children's Hospital
NewYork-Presbyterian / Weill Cornell Medical Center
NewYork-Presbyterian Lower Manhattan Hospital
(NewYork-Presbyterian has another 5 hospitals in its network)
Yale New Haven Medical Center
UMass Medical Center
Coler/Goldwater Hospital
Metropolitan Hospital
Mount Sinai South Nassau Medical Center
Bellevue Hospital electrostatic
NYU Langone
Lincoln hospital
Westchester County Medical Center
Harlem Hospital
Wyckoff Hospital
SUNY Downstate Medical Center
Coney Island Hospital
Kings county Medical Center
Queens Hospital
Methodist Hospital
Jacobi Medical Center
UK North Tees and Hartlepool NHS Foundation Trust
UK ?
Level 3 Distributors or Large Volume Hydrolyte systems users (11):
4 systems to a Food Processing Customer
1 System Pure and Clean
1 System to Puerto Rico
1+ System to Ace Janitorial
2 Systems H2S Safe Treat Inc of Ada, OK
2 Systems BioBlasting LLC of Egg Harbor Township, New Jersey
1 System BOX Bioscience of Mount Pleasant, SC
1 System Colorado Springs, CO
To Investor Relations:
Do you have a link to the recorded CC?
From Investor Relations:
Good Morning,
There will be. They are going to put a link up on our website this morning.. Once it's up I will send it out the shareholders.
From the 2019 10K:
Oil and Gas Industry
World market prices for oil decreased during the past several years in response to increased production coming on line simultaneously with a softening of the growth in demand. The oil and gas industry in the U.S. and elsewhere has experienced unprecedented expansion and prosperity due to an influx of technological advances enabling the discovery and accurate location and identification of significant domestic oil and gas reserves. Advances in drilling technology, fracturing equipment and chemical methodology greatly enhanced recovery rates and revenue growth. This growth surge in supply reduced the United States’ dependency on foreign oil, and, we believe, contributed to lowering the U.S. trade deficit, reducing unemployment rates in oil producing areas, reducing heating and cooling costs, and providing lucrative investment opportunities. However, during 2014 and 2015 the steadily increasing supply of oil on a global scale led to reduced prices and decreased drilling activity in the U.S. From a June 20, 2014 price of $115 per barrel, the price dropped to historic lows below $30 in February 2016. The drop in the market price of oil led to a great reduction in drilling activity causing a corresponding loss of opportunities to sell the company’s products and services in the oil & gas industry. By the end of 2017, the price of oil had recovered to the $50 to $55 range. A stable market in this price range is expected to lead to renewed opportunities in this industry in 2018. As opportunities emerge, we plan to use oil-field service companies to market and distribute our Hydrolyte® and Catholyte products to their clients/customers. Management is currently seeking an appropriate opportunity to re-enter this market.
Management believes that the benefits of our proven technologies continue to be desirable for, and should continue to be used in, hydraulic fracturing drilling worldwide. Some of the benefits of our products and systems include: elimination of highly toxic chemicals currently used for decontamination, reduced negative environmental impact, reduced recovery costs, improved product quality, and potentially opening new areas for oil and gas retrieval. As a result, management is preparing for expanding business opportunities in this sector in the mid-term future. As part of this preparation, Paradigm is developing a large-scale system utilizing Hydrolyte® to decontaminate water and fluid going “down hole” in oil and gas-well drilling; and to decontaminate recovered “frac” water for reuse in the fracking process. Operational experience has shown that Hydrolyte® not only effectively decontaminates the water supply of microbes, but also does not cause corrosive damage to gas and oil recovery equipment; nor does it cause any loss of performance to the other chemicals, additives, and propellants currently used in drilling and fracking processes.
Hydrolyte® also addresses another problem in the oil and gas industry. In a separate application, Hydrolyte® can be used to reduce the sulfur content of crude oil in the ground. There are sulfite-producing microbes in crude oil which cause higher levels of hydrogen sulfide (“H2S”) and “sour” wells with sour crude oil which is less valuable than “sweet” crude which has low H2S. It has been demonstrated that Hydrolyte® is effective in reducing or eliminating these microbes, thus improving the quality and value of the oil recovered from the treated well.
Hydrolyte® can reduce the costs of transporting contaminated water from the wellbore to a treatment facility and back for reuse, thus reducing the need for construction of water processing capacity, providing a substantial reduction in the costs of drilling, and enabling a sustainable increase in efficiency. The company intends to maintain an active marketing program; and, expects that there will be renewed opportunities for revenue growth from the frac drilling and related oil-field applications.
We delivered a large volume order of Hydrolyte® to a distributor of oilfield chemicals for use by one of its customers during 2018 and have delivered, under a 2019 commercial collaboration agreement, additional Hydrolyte® large volume equipment to Meeker, Oklahoma. Collaboration in oilfield/gas industry testing, along with preliminary conversations and observations about the Cannabis market, regarding models of delivery of the fluids to the oil and gas market.
The Hospital Disinfectant That's Making Fracking Greener
A bit dated by very informative
Fracking seems to have more going against it than for it, but a South Carolina-based company is hoping the oil and gas industry will mitigate environmental damages and health concerns with its latest product, Excelyte.
Excelyte is an EPA-approved solution that addresses major controversies associated with fracking: pollution of groundwater with toxic chemicals, release of hydrogen sulfide that endangers oil field workers’ lives, and excess wastewater.
Integrated Environmental Technologies (IET) originally developed the solution as a final surface cleaner to eliminate hospital-acquired infections like tuberculosis, and then to prevent foodborne illnesses in food production. Excelyte has been proven to be 99.9999% effective against HIV, H1N1, Salmonella, E. coli, Listeria, among other bacteria and viruses. The solution’s main active ingredient is hypochlorous acid—a naturally occurring molecule in the human body that fights infection.
Healthcare to food production was a natural extension, but in searching for other applications where bacteria and viruses posed as a deadly threat, IET found an industry that’s desperate to improve its environmental impact: oil and gas.
Excelyte is currently being tested in Utah and New Mexico in its first foray into the oil and gas scene. David LaVance, CEO of IET, said several well-known companies are using the product, but would not reveal which ones.
“We figured out that if our product was really safe for hospitals and for food, that it should be quite safe for oil and gas,” said LaVance. “We’ve done a whole series of tests and now have written papers on it that demonstrate it can be used underground in wells, and it of course has no detrimental effect on the water supply because this is a product that is safe for humans.”
LaVance has spent a majority of his career in healthcare and is also Chairman of the Board of Hologic, a leading provider of diagnostic and imaging systems related to women’s health, such as mammograms and pap tests.
A single frack job takes millions of gallons of water, with only 25-30% of that water recovered for reuse. IET claims that by mixing water with Excelyte’s bacteria and sulfur-fighting properties instead of toxic chemicals, twice as much wastewater can be recovered for reuse in fracking instead of using fresh water.
Hydrogen sulfide, a naturally occurring gas that can be released during oil and gas production, is the most frequent killer of oil field workers. Excelyte is a hydrogen sulfide scavenger that combines chemically to hydrogen sulfide. The solution, which took over five years to develop into a substance fit for production in industrial quantities, is also designed to leave no trace on the environment.
“Our product persists for only 90 days and then it disintegrates,” said LaVance. “It’s not underground for very long and things go back to normal after that. So it’s a quick-acting biocide.”
The state of Utah is optimistic about oil and gas companies using Excelyte to address environmental concerns.
“If companies are looking at this product as a way to prevent some of those things from happening, we’re certainly in favor of it,” said John Baza, director of the Oil, Gas and Mining Division in Utah. “We would encourage that kind of creative and innovative thinking.”
Wherever fracking is involved, controversy has traditionally followed. Concerns range from polluting drinking water with toxic chemicals to setting earthquake records. A community in the North Texan city of Denton, which is believed to hold one of the biggest natural gas reserves in the U.S., recently captured the attention of the energy industry with an attempt to ban hydraulic fracturing due to noise and toxic fumes from fracked wells in their backyard. But the city faces an uphill battle—the U.S. fracking market was valued at $26 billion in 2013 according to BCC Research.
In Utah, where Excelyte is in somewhat of a pilot testing mode, oil field companies are not required to obtain specific government approval to use the product, but are required to report chemical usage in the national database FracFocus.
Despite Excelyte’s impressive properties and promising applications, environmentalists aren’t likely to be overly excited about the product.
“Even if all of the chemicals used for fracking were perfectly benign (and they are not), the wastes still would be highly toxic, because the fluids bring numerous hazardous substances, including radioactive materials, to the surface,” said Deborah Goldberg, an attorney at environmentalist group Earthjustice. “No one yet has found a way to dispose of all of the wastes without creating additional environmental risks.”
Though fracking is by no means a sustainable practice, it is projected to experience further growth well into 2018. If widely adopted, the use of Excelyte could save lives and save water in various processes.
Excelyte has been approved by the National Science Foundation (NSF), U.S. Department of Agriculture (USDA) and the U.S. Environmental Protection Agency (EPA) for use in food production; healthcare; veterinary practices; and the oil and gas industry.
The EPA declined to comment on the solution’s current or projected use in fracking activities.
The solution’s applications in reusing and recycling water would be of particular interest to West Coast states like Colorado, New Mexico, Texas, and California, which have been facing a longstanding drought.
Integrated Environmental Technologies, Ltd. (IEVM) operates through its subsidiary, I.E.T., Inc. and is publicly traded. The company’s products and services are marketed and sold under the umbrella brand name, EcoTreatments.
https://www.forbes.com/sites/rosatrieu/2014/07/22/the-hospital-disinfectant-thats-being-used-in-fracking/#6b6084fe4904
Thank you
Does anyone know the name of the marketing company PCTL hired?
Oil & Gas Industry
Fracking is controversial but there’s no debating the fact that it’s expanding every day. There are 20,000 new wells fracked every year. Regardless of which political party is running Washington D.C., that’s not changing anytime soon. That said, the best thing we can do for the environment is perfect the process through smart technology.
Fracking is water mixed with sand and chemicals to break up rocks and release the natural gas. The process requires massive amounts of water. Those 20,000 wells require five to eight million gallons of water each. That’s as much as 160 billion gallons every year that need to be disinfected to protect the nation’s water supply.
APPLICATIONS
Before putting this fracking mix into the ground, a disinfectant is needed. Excelyte™ is the most effective solution to disinfect the water and prevent groundwater contamination.
Excelyte® kills bacteria and viruses. It also neutralizes some chemicals, like hydrogen sulfide. It does not eliminate heavy metals.
Unlike any other fracking solution, Excelyte™ cleans and protects production equipment from corrosion, creates a safer work environment by targeting and eliminating hydrogen sulfide (the leading cause of gas inhalation deaths among oil/gas workers), leaves no lasting impact on the environment and is undetectable 90 days after use.
Excelyte™ is being adopted by natural gas producers in the western U.S., especially in Utah and New Mexico.
Excelyte™ is considered an industry leader in being able to provide an environmentally conscious solution for disinfecting and sanitizing. It is EPA registered as an antimicrobial. For more than 20 years, Excelyte™ has been used for the enhancement of oil and gas production. It is frac fluid compatible and pH neutral. It is the only EPA-registered disinfectant that has been proven completely effective against all bacteria and virus tested. We provide customers with chemical-free science-based disinfecting, sanitizing and cleaning solutions produced by ECA technology to promote environmental, worker and consumer health safety wherever pathogens must be controlled.
The key active ingredient in Excelyte™ is hypochlorous acid, derived from naturally occurring salt minerals and water.
When it degrades, it turns to salt and water which leaves no ecological footprint. It is a cost-effective alternative to other chemicals currently used such as glutaraldehyde and bleach.
Excelyte’s™ unique ability to disrupt viruses and bacteria cell structure while being able to fully degrade leaving no ecological footprint behind, makes it both strong but safe in many applications. The ability to disrupt the cell structure prevents organisms from mutating and becoming resistant, reduces the possibility of superbugs. It does not become resistant to microbes, as do most chemicals. It kills oil field bacteria with no harmful by-products. Protective equipment and site safety measures are not required for Excelyte™ applications. Once Excelyte™ has fully degraded, it leaves no ecological damage to well sites.
For every one million gallons of water used, we only need to add about 5,000 gallons of Excelyte™ to treat at 2.5ppm. It costs millions of dollars per frack per well but the cost of adding Excelyte™ is a fraction of a percentage of that overall cost.
Excelyte™ has been registered by the EPA for use in the following applications:
Fractured & Produced Water
Sour Wells
Water Flood Injection Waters
Oil and Gas Transmission Lines
Heater Treaters
Hydrocarbon Storage Facilities
THE MAIN AREAS OF USE
Frack Water
Almost every gas well entails a frack job, requiring approximately 80,000 gallons of water. This water can be treated with Excelyte™ solutions to manage bacteria, protecting fracturing fluids and gels, and ensuring polymer and proppant performance. It removes scale and slime build-up from pipes, and cooling water systems can be kept free of biofilm which improves heat exchange values and eliminates microbial induced corrosion (MIC).
Recent data collected from field operations where frack water was treated with Excelyte™ shows that the bacteria levels in the frack water were reduced below the threshold level that would adversely impact stimulation fluids and gels. Produced water may be treated before being revised in stimulation fluids or water floods.
Excelyte™ can be used to enhance production from wells which have been impacted by down-hole growth of bacteria, and other microorganisms, by killing the bacteria and removing the restrictive biofilms. It is a great utility in the reduction of hydrogen sulfide in produced water retention pools and make-up water.
For typical water treatment, mix 5 US gallons of Excelyte™ with 995 US gallons of frack water to 2.5ppm FAC to mitigate and retard the growth from non-public health microorganisms such as anaerobic bacteria, aerobic bacteria and sulfater inducing bacteria to protect fracturing fluids, polymers and gels. Frack jobs require a biocide. An average frack job will require about 800-4,000 gallons of biocide per frack.
Well Maintenance
Excelyte™ is effective in producing wells as a biocide and anti-corrosive agent and has great utility in reduction of hydrogen sulfide in producing wells, reducing cost of reconstruction of well linings. Excelyte™ has demonstrated effectiveness in producing wells, especially in high sulfur geologies. Excelyte™ addresses corrosion and sour well problems in the high-sulfur fields (e.g. Utah, Colorado, Dakotas, and Wyoming).
Typical producing wells in sulfur zones consume in excess of 500 gallons of biocide weekly.
Produced Water Market
Contaminated produced water must be decontaminated before release into the environment or recycled for use. Retention ponds create environmental hazards, harboring heavy metals and bacteria. Reverse Osmosis technologies remove heavy metals and produce “pure” water.
Cooling Towers
Cooling tower water can be treated with low concentrations of Excelyte™ so that bacteria in the tower are controlled. In addition, Excelyte™ removes the scale build-up on fill, pans and in pipes so that a better heat exchange value is maintained throughout the system. Costs for handling, storing and disposing of hazardous chemicals used to treat for bacteria and inhibit scale are dramatically reduced. Furthermore, downtime and maintenance costs for periodic cleaning are eliminated.
RESEARCH PAPERS
EcaFlo™ Anolyte: A Two-Edged Biocide
Dr. Val Dunham, Associate Provost for Research, Distinguished Professor Emeritus – Coastal Carolina University
Electrolytic Biocides: green alternative for stimulation protection and formation biomass remediation
DL Holcomb, TL Zitkus, L Jones – … of the Annual …, 2005 – Southwestern Petroleum Short Course
Green biocides, a promising technology: current and future applications to industry and industrial processes
MA Ashraf, S Ullah, I Ahmad, AK Qureshi… – Journal of the …, 2014 – Wiley Online Library
Case study: evaluation of an oxidative biocide during and after a hydraulic fracturing job in the Marcellus Shale
SM Rimassa, PR Howard, B MacKay… – … Symposium on Oilfield …, 2011 – onepetro.org
Aqueous Solution For Managing Microbes In Oil And Gas Production And Method For Their Production
SA Emmons – US Patent App. 12/907,309, 2010 – Google Patents
http://www.ecotreatments.com/solutions/oil-gas-industry/
David L. Holcomb, Ph.D., Pentagon Technical Services, Inc./ Nissan Chemical America Corp./ Rhino Chemical
Biographical Summary:
David is the president of Pentagon Technical Services, Inc an oil & gas related consulting company based in Florence, Arizona. He is currently retained by Nissan Chemical America, Houston, Texas to develop and develop marketing strategy for unique colloidal chemistry applications for the oil and gas upstream sector as well as associated water treatment industries. His oil and gas industry experience covers 46 years of continuous effort in research, development, technical training and technical marketing for well stimulation, oilfield chemistry and fracture diagnostics technologies. He has worked for Cardinal Chemical, Inc., Smith International Inc.’s Energy Division, Protechnics, a Division of Core Laboratories, FTS International, Inc., Flotek Industries, Inc. and Pentagon Technical Services, Inc. He has held various technical and technology management positions and has developed numerous products and methods for well intervention, most of which are in use today.
His educational background includes receiving his B.S. from Texas State University in biology and chemistry and his M.S., and Ph.D. in Chemical Engineering from the University of Texas. He has written and published over 40 technical and professional papers for SPE, SPEJ, AIChE, AGA, and SWPSC. He has been a distinguished lecturer for SPE (1984-85) on the topic of formation damage, and is an active member of SPE, ACS, and AIChE. He is on the SPE Young Professionals lecture circuit. He is the past chairman of the SPE International Oilfield Chemistry Symposium and the Texas Tech University Southwestern Petroleum Short Course as well as a retired board member for them. He was elected a Distinguished Member of the Denver Section of SPE in 1985. He holds three patents and has three pending in the areas of oilfield chemistry, fracture placement diagnostics, acid fracturing and nanotechnology. He has worked on assignments around the world including the USA, Canada, North Sea (Scotland and Norway), Mexico, Brazil, Ecuador, Australia and Algeria.
PCTL has a minimum of 5 Annihilyzer Systems in the quoting phase for 3 hospital networks (upstate NY, CT and TN). We could get confirm POs any day now.
Conference Call thoughts:
Company is growing
UK Purchase Orders (The BOOM)
Business consultant is bringing in business
Debt is being worked
Company needs more financing however as revenues continue to increase it becomes less of an issue.
Oil and gas is a huge potential revenue maker. If the upcoming field test is successful as it was in the laboratory then we may have a game changer. (Future BANG)
PCTL took ownership of financial reporting lateness and has a plan that should keep them on-time moving forward.
Overall I thought it was a decent call. They really explained the importance of having more distributors, the daily inquiries for distributorships and the costs some distributors are spending to get up and running.
The person who explained the EPA requirements knows his shit.
PCTL is still a struggling company however if they continue to grow and keep their debt in check, they should be OK. It will just take awhile depending on how fast revenues will grow or if they ever land an “Angel Investor”.
Why the "29th"?
Major contract announcement?
Government contract?
Coordination of CC with potential Partner availability?
Buyout announcement?
We will soon find out in T minus 30 minutes!
Why I think the PCT’s US marketing efforts of its patented Annihilyzer® Infection Control System is the most important and earth-shattering agenda item in the upcoming Conference Call:
PCT LTD Announces Agenda for Shareholder Conference Call on Tuesday, September 29, 2020:
https://www.para-con.com/images/docs/PCTL09-09-20.pdf
It is PCTL’s flagship product
The Annihilyzer has the best solution to a multi-billion dollar problem.
Hospital Disinfectant Products Market to Expand at Growth Rate of ~ 5.3% CAGR from 2018 to 2026 to Reach US$ 17.1 Billion through 2026:
There are 4,749 acute care hospitals in the US. The Annihilzyer, a proven system is installed in 14 of the 62 acute hospitals (over 22% market share) in New York city.
The press release dated August 5, 2020 said “additional and ongoing activities in the US Healthcare market include, but are not limited to” so there are probably more deals in the works and hopefully we will find out more during the CC if not sooner.
https://www.para-con.com/images/docs/PCTL08-05-20.pdf
Also in conjunction with the Annihilyzer, the agenda item for additional activities in the healthcare and oil and gas industries is a mystery. A possibility may have to do with water/air. Here are a couple of thoughts:
As I spent many of my younger years working within the HVAC sector, I am well aware of all the issues that must be overcome to help combat our battle against COVID-19. By implementing the use of Anolyte ANK we can help with AHU systems by fogging the supply air with our HOCL, which will provide disinfection against COVID-19 and any other airborne pathogens, bacteria or viruses that are within the airstream. Providing good quality air which is free from harmful microorganisms or viruses can only benefit the occupants within an air conditioned or ventilated building. Good quality air prevents the occurrence of ‘Sick Building Syndrome’. https://investorshub.advfn.com/boards/read_msg.aspx?message_id=158024099
The immune system of vertebrates “naturally” produces hypochlorous acid (HOCl) to fight against bacteria and pathogens. A patented electrochemical technology mirrors the above defense system, allowing the synthesis of HOCl solutions through the electrolysis of water enriched in salts, at the level of a few grams per liter. The system allows for the careful control of the pH of produced solutions, with consequent optimization of their activity. Once the HOCl is introduced into the water system; it is able to remove the biofilm from pipe network; significantly decreasing the level of Legionella colonization; within 8–10 weeks from the beginning of the disinfection approach. The technology has been applied in a variety of healthcare facilities, both in Italy and in neighboring European countries. In the present paper, two successful case studies are briefly presented: Data were obtained from experiences in two different healthcare facilities, one in Italy and the other in Germany. Destruction of biofilm was indirectly testified by an increase of total organic carbon content of water; as a consequence, and because of the dosing of the disinfecting agent, some µg/L of total halomethanes were also formed. However, both compositional features were only observed during the initial stages of the disinfection treatment. https://investorshub.advfn.com/boards/read_msg.aspx?message_id=158025945
We have not penetrated the US Healthcare Infection Control System market greatly other than NYC. We have systems in other hospitals in other states however not on the scale of NYC. I hope that is about to change beyond the systems orders of upstate NY, CT and TN.
An article from March 2020, stated: “We expect to grow at the rate of two hospitals a month for the first part of this year and then to double that for the second half of the year. We have been dubbed a disruptive technology for hospitals. However, it does not have to be limited to hospitals. There are certainly other markets, such as assisted living facilities, schools, even companies and factories that could use this system to reduce sickness.”
Grieco added: “All of our hospital customers using our infection control system and disinfectant are utilising the systems as a front-line defence throughout their facilities, including in all public area such as restrooms, lobbies, waiting rooms, elevators, corridors, cafeterias, etc. all throughout the day and night and in the presence of patients, staff and visitors.”
The Annihilyzer is state of art, cost effective and green technology. There is no other system in the world that has the capabilities of the Annihilyzer. Second to none...
During the June 22, 2020 podcast “We’re moving forward with opening additional depots or expanding our ready depots,” said Grieco. He then elaborated on the Company’s new hospital installations, sharing that they expect two hospital installations to occur each month going forward.
Can anyone name a SUPERIOR Infection Control System than the ANNIHILYZER?
I didn’t think so.